| Serum Mesothelin for Diagnosing Malignant Pleural Mesothelioma: An Individual Patient Data Meta-Analysis. K Hollevoet, JB Reitsma, J Creaney, BD Grigoriu, BW Robinson, ... Journal of clinical oncology: official journal of the American Society of …, 2012 | 256 | 2012 |
| Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front‐line therapy of pleural mesothelioma and correlation of tumor … R Hassan, E Sharon, A Thomas, J Zhang, A Ling, M Miettinen, ... Cancer 120 (21), 3311-3319, 2014 | 184 | 2014 |
| Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma K Hollevoet, K Nackaerts, J Thimpont, P Germonpré, L Bosquée, ... American journal of respiratory and critical care medicine 181 (6), 620-625, 2010 | 113 | 2010 |
| In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer K Hollevoet, E Mason-Osann, X Liu, S Imhof-Jung, G Niederfellner, ... Molecular cancer therapeutics 13 (8), 2040-2049, 2014 | 101 | 2014 |
| Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma K Hollevoet, K Nackaerts, R Gosselin, W De Wever, L Bosquée, ... Journal of Thoracic Oncology 6 (11), 1930-1937, 2011 | 88 | 2011 |
| State of play and clinical prospects of antibody gene transfer K Hollevoet, PJ Declerck Journal of translational medicine 15, 1-19, 2017 | 70 | 2017 |
| The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor K Hollevoet, K Nackaerts, O Thas, J Thimpont, P Germonpré, P De Vuyst, ... Chest 141 (2), 477-484, 2012 | 46 | 2012 |
| Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study K Hollevoet, J Van Cleemput, J Thimpont, P De Vuyst, L Bosquée, ... Journal of Thoracic Oncology 6 (5), 889-895, 2011 | 43 | 2011 |
| Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serum K Hollevoet, D Bernard, F De Geeter, N Walgraeve, A Van den Eeckhaut, ... Clinical chemistry 55 (7), 1431-1433, 2009 | 37 | 2009 |
| Prolonged in vivo expression and anti-tumor response of DNA-based anti-HER2 antibodies K Hollevoet, E De Smidt, N Geukens, P Declerck Oncotarget 9 (17), 13623, 2018 | 29 | 2018 |
| Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes E Kolyvas, M Rudloff, M Poruchynsky, R Landsman, K Hollevoet, ... Oncotarget 8 (6), 9189, 2017 | 28 | 2017 |
| Thoracoscopy: advances and increasing role for interventional pulmonologists P Lee, E Folch Seminars in Respiratory and Critical Care Medicine 39 (06), 693-703, 2018 | 27 | 2018 |
| Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results E Mason-Osann, K Hollevoet, G Niederfellner, I Pastan Scientific reports 5 (1), 10832, 2015 | 27 | 2015 |
| Combining the antimesothelin immunotoxin SS1P with the BH3-mimetic ABT-737 induces cell death in SS1P-resistant pancreatic cancer cells K Hollevoet, A Antignani, DJ FitzGerald, I Pastan Journal of immunotherapy 37 (1), 8-15, 2014 | 24 | 2014 |
| Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers E Sharon, J Zhang, K Hollevoet, SM Steinberg, I Pastan, M Onda, ... Clinical chemistry and laboratory medicine 50 (4), 721-725, 2012 | 23 | 2012 |
| DNA-based delivery of checkpoint inhibitors in muscle and tumor enables long-term responses with distinct exposure L Jacobs, E De Smidt, N Geukens, P Declerck, K Hollevoet Molecular Therapy 28 (4), 1068-1077, 2020 | 21 | 2020 |
| Fibulin-3 as a biomarker for pleural mesothelioma K Hollevoet, E Sharon N Engl J Med 368 (2), 189, 2013 | 19 | 2013 |
| Bridging the clinical gap for DNA-based antibody therapy through translational studies in sheep K Hollevoet, S De Vleeschauwer, E De Smidt, G Vermeire, N Geukens, ... Human Gene Therapy 30 (11), 1431-1443, 2019 | 18 | 2019 |
| Methylation-associated partial down-regulation of mesothelin causes resistance to anti-mesothelin immunotoxins in a pancreatic cancer cell line K Hollevoet, E Mason-Osann, F Müller, I Pastan PLoS One 10 (3), e0122462, 2015 | 17 | 2015 |
| 31st annual meeting and associated programs of the society for immunotherapy of cancer (Sitc 2016): Part two: National harbor, md, USA. 9-13 November 2016 C Ager, M Reilley, C Nicholas, T Bartkowiak, A Jaiswal, M Curran, ... Journal for ImmunoTherapy of Cancer 4, 107-221, 2016 | 12 | 2016 |
Jan P van MeerbeeckUniversiteit Antwerpen - Universitair Ziekenhuis Antwerpen- Universiteit GentVerified email at uza.be
